PEA dosage: what doses the clinical trials actually used
300 to 1,200 mg a day, most commonly 600 mg split into two. But the number that matters commercially is not the dose — it is the duration. Roughly 40% of the total benefit accrues after day 30, which means a one-month trial systematically under-reads the ingredient.
Published July 2026 by the PEAOID technical team · reviewed against the primary literature
Scope and a necessary disclaimer
This page summarises the doses used in published clinical research on palmitoylethanolamide. It is written for formulators, regulatory teams and healthcare professionals evaluating the ingredient. It is not a dosing recommendation for any individual, and PEAOID does not give medical advice or supply consumers. Permissible dose levels and claim language on a finished product are determined by the regulator in the market of sale, not by the clinical literature.
The dose range used in trials
| Daily dose | Regimen | Studied in | Duration |
|---|---|---|---|
| 300 mg | Once or twice daily | Knee osteoarthritis (low arm); sciatic nerve compression (low arm) | 3–8 wk |
| 350 mg | Single dose before bed | Sleep-onset latency | 8 wk |
| 600 mg | 300 mg twice daily | Sciatic nerve compression; diabetic peripheral neuropathy; knee osteoarthritis; carpal tunnel syndrome | 3–9 wk |
| 700 mg | Once daily | Cognition and BDNF in healthy young adults | 6 wk |
| 800 mg | 400 mg PEA + 40 mg polydatin twice daily | Endometriosis-associated pelvic pain | 3 mo |
| 1,200 mg | 600 mg twice daily | Fibromyalgia (loading month); migraine prevention (with melatonin); central and peripheral sensitization in healthy volunteers | 4 wk–3 mo |
| Up to 1,800 mg | Divided | Historical Impulsin respiratory program, 1972–77 | 8 wk |
Two observations from this table. First, 600 mg per day, given as 300 mg twice daily, is the modal regimen across the modern literature — it appears in the sciatica, diabetic neuropathy, osteoarthritis and carpal tunnel trials. Second, the ceiling is high: 1,800 mg per day was used in the historical program and reported as well tolerated, and the rat NOAEL sits above 1,000 mg/kg/day, which corresponds to a human equivalent well into the grams.
The load-then-maintain pattern
Several protocols in the literature use a higher dose for the first month and step down afterwards. The fibromyalgia study is the clearest example: 600 mg twice daily for month one, then 300 mg twice daily for months two and three. Clinical summaries describe this as the common practical approach — establish effect at 1,200 mg/day, then reduce to 600 mg/day for maintenance once the response is established.
For a finished-product brand, this has a straightforward implication: a two-tier pack strategy, or dosing instructions that distinguish an initial period from ongoing use, follows the clinical evidence more faithfully than a single flat dose.
Onset: why 30 days is not a fair test
This is the single most commercially important finding in the PEA dosing literature, and it is routinely ignored.
PEA works through a transcriptional mechanism. It activates PPAR-alpha, which changes gene expression, which changes what the cell builds over the following days and weeks. That is inherently slower than inhibiting an enzyme that already exists. So the onset profile looks nothing like an analgesic.
The 2024 extended-treatment meta-analysis quantified it. Across nine studies and 742 patients:
- Month one produced a 2.08-point pain reduction, about 35% of baseline — roughly 60% of the total benefit observed.
- Between day 30 and day 60, a further 1.36-point reduction accrued (95% CI 0.98–1.74, p<0.01).
- Cumulatively by day 60, a 3.44-point reduction.
And the 2025 meta-analysis found the effect continuing to deepen well beyond that: SMD −0.90 at six weeks, −0.98 at eight weeks, −1.16 at 24–26 weeks.
What this means when you are planning a product
The practical implication is about evaluation period, not about what a pack may claim. A study, consumer trial or internal assessment that runs only 30 days captures roughly 60% of the observed effect and will under-read the ingredient. Pack architecture and consumer communication are commercial decisions for you, and any statement made on a finished product must be substantiated and permissible under the law of the market of sale. PEAOID supplies raw material; we do not draft or approve label claims.
Some trials do show earlier signal — the sciatica study reported substantial VAS improvement at three weeks — but three weeks appears to be the floor rather than the norm.
Dose by indication, as studied
| Indication | Dose used | Duration | Evidence level |
|---|---|---|---|
| Sciatic nerve compression pain | 300 or 600 mg/d | 3 wk | RCT, n = 636. NNT 1.5 at 600 mg. |
| Diabetic peripheral neuropathy | 600 mg/d | 8 wk | Quadruple-blind RCT, n = 66. |
| Knee osteoarthritis | 300 or 600 mg/d | 8 wk | Double-blind, placebo-controlled, 3 arms, n = 111. |
| Fibromyalgia (add-on) | 1,200 → 600 mg/d | 3 mo | Observational, n = 80. Not placebo-controlled. |
| Endometriosis-associated pain | 800 mg/d with polydatin | 3 mo | Meta-analysis of 4 studies; authors rate quality as poor. |
| Migraine prevention | 1,200 mg/d with melatonin | 3 mo | RCT, n = 60. Combination product. |
| Sleep onset | 350 mg pre-bed | 8 wk | Double-blind RCT, n = 103. Benefit in the long-latency subgroup only. |
| Cognition / BDNF | 700 mg/d | 6 wk | Randomized crossover, n = 39, healthy adults. |
| Central sensitization | 1,200 mg/d | 4 wk | Randomized crossover, n = 14, healthy volunteers. |
| Carpal tunnel syndrome | 600 mg/d | 60 d | Largely negative. Authors concluded the dose was insufficient for this population. |
| Spinal cord injury neuropathic pain | Ultra-micronized PEA | 12 wk | Negative trial, n = 73. |
Does the grade change the dose?
In principle yes, in practice the literature does not support a clean conversion factor. Most modern human trials used micronized or ultra-micronized material at 300–1200 mg/day, so those dose figures are already grade-specific to milled PEA. Unmicronized material at the same milligram dose delivered measurably less systemic exposure in animal work and failed to produce a significant effect in the oral arm of the pivotal rat comparison.
What that means practically: do not assume a standard-grade product at 400 mg is equivalent to a micronized product at 400 mg. It is not, and the literature was not generated on standard-grade material. If cost pressure pushes you toward the coarser grade, the honest response is to acknowledge the difference rather than to quietly rely on trial data generated with a different form.
The particle-size evidence in full
Safety at these doses
The dose range in the literature sits a long way below any observed toxicity threshold. The GLP-compliant rat developmental toxicity study found no adverse findings at 1,000 mg/kg/day, the highest dose tested. The pooled clinical safety review across roughly 1,590 patients found that for courses up to 49 days the data exclude serious adverse reactions occurring at one in 200 or more, and pooled dropout ran lower on PEA than on placebo.
The gaps are duration and population rather than dose: no controlled data beyond twelve months, no human data in pregnancy or lactation, no published pharmacokinetic interaction studies.
References
- Schweiger V, Polati E, et al. Extended treatment with micron-size oral palmitoylethanolamide in chronic pain: a systematic review and meta-analysis. Nutrients 2024;16(11):1653.
- Viña I, López-Moreno M. Meta-analysis of palmitoylethanolamide in pain management. Nutrition Reviews 2025;83(7):e1604–e1618.
- Lang-Illievich K, et al. PEA in the treatment of chronic pain: meta-analysis of double-blind RCTs. Nutrients 2023;15(6):1350.
- Steels E, et al. A double-blind randomized placebo-controlled study assessing safety, tolerability and efficacy of PEA for symptoms of knee osteoarthritis. Inflammopharmacology 2019;27(3):475–485.
- Pickering E, et al. A randomized controlled trial of PEA for diabetic-related peripheral neuropathic pain. Inflammopharmacology 2022;30(6):2063–2077.
- Del Giorno R, et al. Palmitoylethanolamide in fibromyalgia. Pain and Therapy 2015.
- Rao A, et al. Palmitoylethanolamide for sleep disturbance. Sleep Science and Practice 2021.
- Kim N, et al. Formulated palmitoylethanolamide supplementation improves parameters of cognitive function and BDNF levels in young healthy adults. Nutrients 2024;16(4):489.
- Gabrielsson L, Mattsson S, Fowler CJ. PEA for the treatment of pain. Br J Clin Pharmacol 2016. PMID 27220803
- Deshmukh NS, et al. Palmitoylethanolamide: prenatal developmental toxicity study in rats. Int J Toxicol 2021;40(2):161–170.
Request a specification, a sample, or a quotation
Send us your target dose, format and volume. Our technical team replies with a full documentation pack — specification, method summary, batch CoA and regulatory dossier — within one business day.